Last reviewed · How we verify
Liposomal paclitaxel and capecitabine
Liposomal paclitaxel and capecitabine is a Small molecule drug developed by Nanjing Sike Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Liposomal paclitaxel and capecitabine |
|---|---|
| Sponsor | Nanjing Sike Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (PHASE3)
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE3)
- Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis (PHASE4)
- Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal paclitaxel and capecitabine CI brief — competitive landscape report
- Liposomal paclitaxel and capecitabine updates RSS · CI watch RSS
- Nanjing Sike Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Liposomal paclitaxel and capecitabine
What is Liposomal paclitaxel and capecitabine?
Liposomal paclitaxel and capecitabine is a Small molecule drug developed by Nanjing Sike Pharmaceutical Co., Ltd..
Who makes Liposomal paclitaxel and capecitabine?
Liposomal paclitaxel and capecitabine is developed by Nanjing Sike Pharmaceutical Co., Ltd. (see full Nanjing Sike Pharmaceutical Co., Ltd. pipeline at /company/nanjing-sike-pharmaceutical-co-ltd).
What development phase is Liposomal paclitaxel and capecitabine in?
Liposomal paclitaxel and capecitabine is in Phase 1.